The 2022 Tandem Meetings | Recent advances & unmet needs in BPDCN
Hemant Murthy, MD, Mayo Clinic Florida, Jacksonville, FL, discusses the unmet needs of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Despite recent advances with clinical trials evaluating tagraxofusp, and antibody-drug conjugates (NCT03386513) and CAR-Ts targeting CD123 (NCT03190278), there remains an unmet need in the older population of patients who make up a large proportion of BPDCN. Some older patients that have been treated with venetoclax have been able to progress to myeloablative transplant, but the unmet need still lies with patients unable to undergo these intensive treatments. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
